BioCryst Pharmaceuticals Former Chief Business Officer Megan Sniecinski's 2021 pay jumps 294% to $7.9M
BioCryst Pharmaceuticals reports 2021 executive compensation
By ExecPay News
Published: April 25, 2022
BioCryst Pharmaceuticals reported fiscal year 2021 executive compensation information on April 25, 2022.
In 2021, six executives at BioCryst Pharmaceuticals received on average a compensation package of $4.9M, a 45% increase compared to previous year.
Average pay of disclosed executives at BioCryst Pharmaceuticals
Megan T. Sniecinski, Former Chief Business Officer, received $7.9M in total, which increased by 294% compared to 2020. 88% of Sniecinski's compensation, or $7M, was in option awards. Sniecinski also received $286K in salary and $691K in other compensation.
For fiscal year 2021, the median employee pay was $273,522 at BioCryst Pharmaceuticals. Therefore, the ratio of Megan T. Sniecinski's pay to the median employee pay was 29 to one.
Jon P. Stonehouse, Chief Executive Officer, received a compensation package of $7.1M, which increased by 17% compared to previous year. 64% of the compensation package, or $4.5M, was in option awards.
Helen M. Thackray, Chief R&D Officer, earned $6.9M in 2021.
Anthony J. Doyle, Chief Financial Officer, received $2.9M in 2021, which decreases by 30% compared to 2020.
William P. Sheridan, Chief Medical Officer, earned $2.5M in 2021, a 6% decrease compared to previous year.
Yarlagadda S. Babu, Chief Discovery Officer, received $2.4M in 2021, which increases by 5% compared to 2020.
Related executives
Jon Stonehouse
BioCryst Pharmaceuticals
Chief Executive Officer
Anthony Doyle
BioCryst Pharmaceuticals
Chief Financial Officer
Helen Thackray
BioCryst Pharmaceuticals
Chief R&D Officer
Yarlagadda Babu
BioCryst Pharmaceuticals
Chief Discovery Officer
William Sheridan
BioCryst Pharmaceuticals
Chief Medical Officer
Megan Sniecinski
BioCryst Pharmaceuticals
Former Chief Business Officer
You may also like
Source: SEC filing on April 25, 2022.